A detailed history of Wellington Management Group LLP transactions in Design Therapeutics, Inc. stock. As of the latest transaction made, Wellington Management Group LLP holds 214,310 shares of DSGN stock, worth $818,664. This represents 0.0% of its overall portfolio holdings.

Number of Shares
214,310
Holding current value
$818,664
% of portfolio
0.0%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

BUY
$2.27 - $4.03 $486,483 - $863,669
214,310 New
214,310 $863,000
Q2 2023

Aug 14, 2023

SELL
$4.99 - $7.64 $239,305 - $366,391
-47,957 Reduced 8.71%
502,375 $3.16 Million
Q1 2023

May 12, 2023

SELL
$5.5 - $9.77 $1.06 Million - $1.88 Million
-192,408 Reduced 25.91%
550,332 $3.18 Million
Q4 2022

Feb 13, 2023

SELL
$7.86 - $17.2 $1.62 Million - $3.54 Million
-206,033 Reduced 21.72%
742,740 $7.62 Million
Q3 2022

Nov 14, 2022

SELL
$14.09 - $25.57 $1.55 Million - $2.81 Million
-109,876 Reduced 10.38%
948,773 $15.9 Million
Q2 2022

Aug 15, 2022

BUY
$9.91 - $17.33 $589,407 - $1.03 Million
59,476 Added 5.95%
1,058,649 $14.8 Million
Q1 2022

May 16, 2022

BUY
$11.17 - $20.89 $1.6 Million - $3 Million
143,635 Added 16.79%
999,173 $16.1 Million
Q4 2021

Feb 11, 2022

SELL
$13.64 - $21.41 $1.36 Million - $2.14 Million
-100,050 Reduced 10.47%
855,538 $18.3 Million
Q3 2021

Nov 15, 2021

BUY
$13.99 - $20.03 $227,001 - $325,006
16,226 Added 1.73%
955,588 $14 Million
Q2 2021

Aug 16, 2021

SELL
$19.02 - $29.78 $3.85 Million - $6.03 Million
-202,623 Reduced 17.74%
939,362 $18.5 Million
Q1 2021

May 17, 2021

BUY
$29.52 - $41.49 $33.7 Million - $47.4 Million
1,141,985 New
1,141,985 $33.5 Million

Others Institutions Holding DSGN

About Design Therapeutics, Inc.


  • Ticker DSGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 55,807,900
  • Market Cap $213M
  • Description
  • Design Therapeutics, Inc. a preclinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of genetic diseases caused by nucleotide repeat expansions. The company's portfolio of products comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ syste...
More about DSGN
Track This Portfolio

Track Wellington Management Group LLP Portfolio

Follow Wellington Management Group LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Wellington Management Group LLP, based on Form 13F filings with the SEC.

News

Stay updated on Wellington Management Group LLP with notifications on news.